These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1116154)

  • 21. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity and pharmacokinetics of a new antifolate, 2,4-diamino-5-adamantyl-6-methylpyrimidine, in dogs.
    Zakrzewski SF; Pavelic Z; Greco WR; Bullard G; Creaven PJ; Mihich E
    Cancer Res; 1982 Jun; 42(6):2177-83. PubMed ID: 7074598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of single chain forms of urokinase-type plasminogen activator.
    Stump DC; Kieckens L; De Cock F; Collen D
    J Pharmacol Exp Ther; 1987 Jul; 242(1):245-50. PubMed ID: 3612530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic studies of [14C]-flumecinol in humans.
    Klebovich I; Csetényi J; Kerpel-Fronius S; Vereczkey L
    Arzneimittelforschung; 1987 Mar; 37(3):368-71. PubMed ID: 3593454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
    Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
    Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine).
    Rahmani R; Bruno R; Iliadis A; Favre R; Just S; Barbet J; Cano JP
    Cancer Res; 1987 Nov; 47(21):5796-9. PubMed ID: 3664483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
    Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
    Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of exaprolol, a new beta-blocker, in rats.
    Trnovec T; Zemánek M; Faberová V; Bezek S; Durisová M; Ujházy E; Tomcíková O
    Drug Metab Dispos; 1982; 10(5):547-50. PubMed ID: 6128208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of vinblastine-loaded platelets utilized in the treatment of platelet-phagocytizing tumors.
    Panasci LC; Comis R; Ginsberg S; Rudolph A; Theodorakis M; Klag M; Fitzpatrick A; Rubert M; Cable R; Davey F
    Cancer Treat Rep; 1980; 64(12):1227-33. PubMed ID: 7193519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
    Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).
    Stewart DJ; Benjamin RS; Zimmerman S; Caprioli RM; Wallace S; Chuang V; Calvo D; Samuels M; Bonura J; Loo TL
    Cancer Res; 1983 Feb; 43(2):917-20. PubMed ID: 6681533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods.
    Boré P; Rahmani R; van Cantfort J; Focan C; Cano JP
    Cancer Chemother Pharmacol; 1989; 23(4):247-51. PubMed ID: 2924381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood.
    Urien S; Brée F; Breillout F; Bastian G; Krikorian A; Tillement JP
    Cancer Chemother Pharmacol; 1993; 32(3):231-4. PubMed ID: 8500229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics of vindesine.
    Nelson RL; Dyke RW; Root MA
    Cancer Chemother Pharmacol; 1979; 2(4):243-46. PubMed ID: 455583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences between vinblastine and vincristine in distribution in the blood of rats and binding by platelets and malignant cells.
    Gout PW; Wijcik LL; Beer CT
    Eur J Cancer (1965); 1978 Nov; 14(11):1167-78. PubMed ID: 738324
    [No Abstract]   [Full Text] [Related]  

  • 37. Studies on the binding of ( 3 H)vinblastine by rat blood platelets in vitro. Effects of colchicine and vincristine.
    Secret CJ; Hadfield JR; Beer CT
    Biochem Pharmacol; 1972 Jun; 21(11):1609-24. PubMed ID: 4646786
    [No Abstract]   [Full Text] [Related]  

  • 38. The pharmacokinetics of [3H]-vincristine in man.
    Bender RA; Castle MC; Margileth DA; Oliverio VT
    Clin Pharmacol Ther; 1977 Oct; 22(4):430-5. PubMed ID: 902455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The reversible binding of vinblastine to platelets: implications for therapy.
    Kelton JG; McDonald JW; Barr RM; Walker I; Nicholson W; Neame PB; Hamid C; Wong TY; Hirsh J
    Blood; 1981 Mar; 57(3):431-8. PubMed ID: 7459430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concentration of vinblastine in human intracerebral tumor and other tissues.
    Stewart DJ; Lu K; Benjamin RS; Leavens ME; Luna M; Yap HY; Loo TL
    J Neurooncol; 1983; 1(2):139-44. PubMed ID: 6678966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.